Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Arcellx, Inc.

Market Cap 6.75B 5.88B 5.42B 5.1B 9.54B 636B 9.61B 64.52B 25.06B 314B 25.34B 24.8B 1,087B P/E 2024
-38.3x
P/E 2025 -16x
Enterprise Value 6.28B 5.47B 5.05B 4.75B 8.88B 592B 8.94B 60.04B 23.32B 292B 23.58B 23.08B 1,011B EV / Sales 2024
33,125,319x
EV / Sales 2025 148,161,186x
Free-Float
88.44%
Yield 2024 *
-
Yield 2025 -

Last Transcript: Arcellx, Inc.

1 day+0.03%
3 months+0.48%
6 months+77.80%
Current year+76.49%
Current year 60.36
Extreme 60.355
115.13
1 year 60.36
Extreme 60.355
115.13
3 years 30.74
Extreme 30.74
115.13
5 years 6.04
Extreme 6.035
115.13
10 years 6.04
Extreme 6.035
115.13
Date Insider Type Main position Quantity % Market Cap.
04-27Tender

Chief Executive Officer

5,603,097 9.5813%
04-27Tender

Director

33,275 0.0569%
04-27Tender

Chief Technology Officer

597,207 1.0212%
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%-.--%+83.00%+221.42% 6.75B
-0.34%-0.08%-12.15%-10.46% 43.44B
+1.56%+7.76%+302.72%+526.19% 33.54B
-4.23%-9.58%+5.89%-23.83% 28.48B
+2.23%+3.66%+6.73%+40.84% 29.2B
-0.57%+3.77%+12.66%+20.42% 25.34B
+0.93%+7.94% - - 14.36B
-0.63%-4.62%+49.70%+101.13% 13.05B
+0.54%-2.27%+3.93%+4.80% 12.67B
-0.12%+0.62%+100.70%+80.86% 12.28B
Average -0.10%+0.73%+61.46%+106.82% 21.91B
Weighted average by Cap. -0.13%+0.77%+62.54%+107.91%

Financials

2024 2025
Net sales 107.94 94.04 86.69 81.54 152.55 10.17K 153.63 1.03K 400.56 5.01K 405.14 396.46 17.38K 22.29 19.42 17.9 16.84 31.5 2.1K 31.72 212.96 82.71 1.04K 83.65 81.86 3.59K
Net income -107M -93.53M -86.22M -81.1M -152M -10.12B -153M -1.03B -398M -4.99B -403M -394M -17.28B -229M -199M -184M -173M -324M -21.58B -326M -2.19B -850M -10.63B -859M -841M -36.85B
Net Debt -572M -498M -459M -432M -808M -53.87B -814M -5.46B -2.12B -26.55B -2.15B -2.1B -92.01B -468M -408M -376M -354M -662M -44.12B -666M -4.47B -1.74B -21.74B -1.76B -1.72B -75.36B
Logo Arcellx, Inc.
Arcellx Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering immunotherapies for patients with cancer and other incurable diseases. Its lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel, which is being evaluated in its pivotal Phase II iMMagine-1 and the Phase III iMMagine-3 trials in patients with relapsed or refractory multiple myeloma (rrMM). Anitocabtagene is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes its novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. It is also developing two clinical-stage ARC-SparX programs in Phase I trials: ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
Employees
209
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. ACLX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!